Fintech research and innovation in the pharmaceutical sector have been stagnant in the last quarter.
The latest figures show that the number of fintech patent applications in the industry was nine in the three months ending March – the same as nine in the same period in 2021.
The figures for fintech-related patent grants follow a different pattern from filing documents – shrinking from seven in the three months ending March 2021 to three in the same period in 2022.
The data is compiled by GlobalData, which tracks patent and grant applications from official offices around the world. Using textual analysis as well as official patent classifications, these patents are grouped into key thematic areas and relate to key companies in various industries.
Fintech is one of the key areas monitored by GlobalData. It has been identified as a key destructive force facing companies in the coming years, and is one of the areas in which companies currently investing resources are expected to benefit.
The figures also give an idea of the biggest innovators in the sector.
Johnson & Johnson was the best fintech technology innovator in the pharmaceutical sector in the last quarter. The company, headquartered in the United States, filed six fintech patents in the three months ending March. That’s more than two in the same period in 2021.
It was followed by South Korean-based Hanmi Science Co Ltd with one fintech patent application, US-based BridgeBio Pharma Inc (1 appendix) and US-based Pfizer Inc (1 appendix).